New therapeutic options for metastatic malignant insulinomas

Clinical Endocrinology

Volumn 75, Issue 3, 2011, Pages 277-284

  De Herder, Wouter W ^a   Van Schaik, Ellen ^a   Kwekkeboom, Dik ^a   Feelders, Richard A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AFFINITOR; ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DACARBAZINE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GLUCOSE; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; THALOMIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANOREXIA; APHTHOUS STOMATITIS; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DISEASE CLASSIFICATION; DRY SKIN; DYSGEUSIA; EPISTAXIS; FATIGUE; FEVER; GLUCOSE BLOOD LEVEL; HAIR DISCOLORATION; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULINOMA; LIVER RESECTION; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAIL DISEASE; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; INDOLES; INSULINOMA; LIVER NEOPLASMS; PANCREATIC NEOPLASMS; PYRROLES; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SIROLIMUS; SOMATOSTATIN;

EID: 79961243200     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04145.x     Document Type: Review

References (84)

1. de Herder, W.W., Niederle, B., Scoazec, J.Y., et al. (2006) Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology, 84, 183-188. (Pubitemid 46361052)
2. de Herder, W.W., Krenning, E.P., van Eijck, C.H., et al. (2004) Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas. Endocrine-Related Cancer, 11, 19-34. (Pubitemid 38419721)
3. Oberg, K., (2010) Pancreatic endocrine tumors. Seminars in Oncology, 37, 594-618.
4. Kulke, M.H., Anthony, L.B., Bushnell, D.L., et al. (2010) NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas, 39, 735-752.
5. Vanderveen, K., &, Grant, C., (2010) Insulinoma. Cancer Treatment and Research, 153, 235-252.
6. Mathur, A., Gorden, P., &, Libutti, S.K., (2009) Insulinoma. The Surgical Clinics of North America, 89, 1105-1121.
7. Zhao, Y.P., Zhan, H.X., Zhang, T.P., et al. (2011) Surgical management of patients with insulinomas: Result of 292 cases in a single institution. Journal of Surgical Oncology, 103, 169-174.
8. Danforth Jr, D.N., Gorden, P., &, Brennan, M.F., (1984) Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery, 96, 1027-1037.
9. Jonkers, Y.M., Claessen, S.M., Perren, A., et al. (2005) Chromosomal instability predicts metastatic disease in patients with insulinomas. Endocrine-Related Cancer, 12, 435-447. (Pubitemid 40896457)
10. Jonkers, Y.M., Claessen, S.M., Veltman, J.A., et al. (2006) Molecular parameters associated with insulinoma progression: chromosomal instability versus p53 and CK19 status. Cytogenetic and Genome Research, 115, 289-297. (Pubitemid 44832032)
11. Jonkers, Y.M., Claessen, S.M., Feuth, T., et al. (2006) Novel candidate tumour suppressor gene loci on chromosomes 11q23-24 and 22q13 involved in human insulinoma tumourigenesis. The Journal of Pathology, 210, 450-458. (Pubitemid 44830605)
12. Jonkers, Y.M., Claessen, S.M., Perren, A., et al. (2007) DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients. Endocrine-Related Cancer, 14, 769-779. (Pubitemid 350074065)
13. Jonkers, Y.M., Ramaekers, F.C., &, Speel, E.J., (2007) Molecular alterations during insulinoma tumorigenesis. Biochimica et Biophysica Acta, 1775, 313-332. (Pubitemid 46899340)
14. Pape, U.F., Berndt, U., Muller-Nordhorn, J., et al. (2008) Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer, 15, 1083-1097.
15. Pape, U.F., Jann, H., Muller-Nordhorn, J., et al. (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer, 113, 256-265.
16. Strosberg, J., Gardner, N., &, Kvols, L., (2009) Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas, 38, 255-258.
17. Rindi, G., Kloppel, G., Alhman, H., et al. (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv, 449, 395-401. (Pubitemid 44451313)
18. Modlin, I.M., Oberg, K., Chung, D.C., et al. (2008) Gastroenteropancreatic neuroendocrine tumours. The Lancet Oncology, 9, 61-72.
19. Kloppel, G., Rindi, G., Perren, A., et al. (2010) The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Archiv, 456, 595-597.
20. Bosman, F.T., Carneiro, F., Hruban, R.H., et al. (2010) WHO Classification of Tumours of the Digestive System. International Agency Research Cancer, WHO.
21. Altszuler, N., Moraru, E., &, Hampshire, J., (1977) On the mechanism of diazoxide-induced hyperglycemia. Diabetes, 26, 931-935. (Pubitemid 8205502)
22. Goode, P.N., Farndon, J.R., Anderson, J., et al. (1986) Diazoxide in the management of patients with insulinoma. World Journal of Surgery, 10, 586-592. (Pubitemid 16096415)
23. Gill, G.V., Rauf, O., &, MacFarlane, I.A., (1997) Diazoxide treatment for insulinoma: a national UK survey. Postgraduate Medical Journal, 73, 640-641. (Pubitemid 27464460)
24. Luna, B., &, Feinglos, M.N., (2001) Drug-induced hyperglycemia. The Journal of the American Medical Association, 286, 1945-1948. (Pubitemid 33010204)
25. Brodows, R.G., &, Campbell, R.G., (1974) Control of refractory fasting hypoglycemia in a patient with suspected insulinoma with diphenylhydantoin. The Journal of Clinical Endocrinology and Metabolism, 38, 159-162.
26. Aderka, D., Shaklai, M., Doron, M., et al. (1975) Phenytoin in metastatic insulinoma. The Journal of the American Medical Association, 234, 1119.
27. Lamberts, S.W., van der Lely, A.J., de Herder, W.W., et al. (1996) Octreotide. The New England Journal of Medicine, 334, 246-254. (Pubitemid 26030676)
28. Vezzosi, D., Bennet, A., Rochaix, P., et al. (2005) Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. European Journal of Endocrinology, 152, 757-767. (Pubitemid 40744545)
29. Vezzosi, D., Bennet, A., Courbon, F., et al. (2008) Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism. Clinical Endocrinology (Oxford), 68, 904-911. (Pubitemid 351703950)
30. Wade, A.N., Cheng, G., Teitelbaum, U., et al. (2011) Amelioration of hypoglycemia with octreotide therapy in metastatic insulinoma with positive octreotide scan. Pancreas, 40, 173-175.
31. Oberg, K., Kvols, L., Caplin, M., et al. (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Annals of Oncology, 15, 966-973. (Pubitemid 39004355)
32. Oberg, K., Ferone, D., Kaltsas, G., et al. (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. Neuroendocrinology, 90, 209-213.
33. Fjallskog, M.L., Ludvigsen, E., Stridsberg, M., et al. (2003) Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Medical Oncology, 20, 59-67. (Pubitemid 36344027)
34. Portela-Gomes, G.M., Stridsberg, M., Grimelius, L., et al. (2007) Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas-predominance of receptor subtype 4. Endocrine Pathology, 18, 79-85. (Pubitemid 47574991)
35. Healy, M.L., Dawson, S.J., Murray, R.M., et al. (2007) Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma. Internal Medicine Journal, 37, 406-409. (Pubitemid 47029891)
36. Cheng, P.N., &, Saltz, L.B., (1999) Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer, 86, 944-948. (Pubitemid 29439847)
37. Eriksson, B., Annibale, B., Bajetta, E., et al. (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology, 90, 214-219.
38. Moertel, C.G., (1987) Karnofsky memorial lecture. An odyssey in the land of small tumors. Journal of Clinical Oncology, 5, 1502-1522.
39. Moertel, C.G., Hanley, J.A., &, Johnson, L.A., (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. The New England Journal of Medicine, 303, 1189-1194. (Pubitemid 11207582)
40. Moertel, C.G., Lefkopoulo, M., Lipsitz, S., et al. (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. The New England Journal of Medicine, 326, 519-523.
41. Dominguez, S., Denys, A., Madeira, I., et al. (2000) Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. European Journal of Gastroenterology & Hepatology, 12, 151-157. (Pubitemid 30166679)
42. Fjallskog, M.L., Sundin, A., Westlin, J.E., et al. (2002) Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Medical Oncology, 19, 35-42. (Pubitemid 34587755)
43. Fjallskog, M.L., Janson, E.T., Falkmer, U.G., et al. (2008) Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology, 88, 53-58. (Pubitemid 352009119)
44. Chandra, P., Yarandi, S.S., Khazai, N., et al. (2010) Management of intractable hypoglycemia with Yttirum-90 radioembolization in a patient with malignant insulinoma. American Journal of the Medical Sciences, 340, 414-417.
45. Ho, K.W., Wong, C.C., Balalla, B., et al. (2006) Malignant insulinomas with hepatic metastases successfully treated with selective internal radiation therapy. Clinical Endocrinology (Oxford), 65, 410-411.
46. Starke, A., Saddig, C., Mansfeld, L., et al. (2005) Malignant metastatic insulinoma-postoperative treatment and follow-up. World Journal of Surgery, 29, 789-793. (Pubitemid 41187545)
47. Hodul, P.J., Strosberg, J.R., &, Kvols, L.K., (2008) Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control, 15, 314-321.
48. 3]octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology, 26, 2124-2130.
49. Kwekkeboom, D.J., Krenning, E.P., Lebtahi, R., et al. (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology, 90, 220-226.
50. Kwekkeboom, D.J., de Herder, W.W., van Eijck, C.H., et al. (2010) Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Seminars in Nuclear Medicine, 40, 78-88.
51. Kwekkeboom, D.J., de Herder, W.W., &, Krenning, E.P., (2011) Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinology & Metabolism Clinics of North America, 40, 173-185.
52. Delaunoit, T., Ducreux, M., Boige, V., et al. (2004) The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? European Journal of Cancer, 40, 515-520. (Pubitemid 38220767)
53. Kouvaraki, M.A., Ajani, J.A., Hoff, P., et al. (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. Journal of Clinical Oncology, 22, 4762-4771.
54. Rougier, P., Oliveira, J., Ducreux, M., et al. (1991) Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin. European Journal of Cancer, 27, 1380-1382.
55. Rivera, E., &, Ajani, J.A., (1998) Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. American Journal of Clinical Oncology, 21, 36-38. (Pubitemid 28092969)
56. Turner, N.C., Strauss, S.J., Sarker, D., et al. (2010) Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. British Journal of Cancer, 102, 1106-1112.
57. Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer, 45, 228-247.
58. Bogaerts, J., Ford, R., Sargent, D., et al. (2009) Individual patient data analysis to assess modifications to the RECIST criteria. European Journal of Cancer, 45, 248-260.
59. Strosberg, J.R., Fine, R.L., Choi, J., et al. (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 117, 268-275.
60. Ramanathan, R.K., Cnaan, A., Hahn, R.G., et al. (2001) Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Annals of Oncology, 12, 1139-1143. (Pubitemid 32834496)
61. Strosberg, J., Hoffe, S., Gardner, N., et al. (2007) Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology, 85, 216-220. (Pubitemid 47123456)
62. Jiao, Y., Shi, C., Edil, B.H., et al. (2011) DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors. Science 331, 1145-1146.
63. Grozinsky-Glasberg, S., Franchi, G., Teng, M., et al. (2008) Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology, 87, 168-181. (Pubitemid 351563811)
64. Grozinsky-Glasberg, S., &, Shimon, I., (2010) The potential role of mTOR inhibitors in the treatment of endocrine tumors. Journal of Endocrinological Investigation, 33, 276-281.
65. Kasajima, A., Pavel, M., Darb-Esfahani, S., et al. (2011) mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer, 18, 181-192.
66. Yao, J.C., Phan, A.T., Chang, D.Z., et al. (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. Journal of Clinical Oncology, 26, 4311-4318.
67. Yao, J.C., Shah, M.H., Ito, T., et al. (2011) Everolimus for advanced pancreatic neuroendocrine tumors. The New England Journal of Medicine, 364, 514-523.
68. Klumpen, H.J., Beijnen, J.H., Gurney, H., et al. (2010) Inhibitors of mTOR. Oncologist, 15, 1262-1269.
69. Fuhrer, D.K., Kobayashi, M., &, Jiang, H., (2001) Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. Diabetes, Obesity and Metabolism, 3, 393-402. (Pubitemid 34030857)
70. di Paolo, S., Teutonico, A., Leogrande, D., et al. (2006) Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes? Journal of the American Society of Nephrology, 17, 2236-2244. (Pubitemid 44141914)
71. Fraenkel, M., Ketzinel-Gilad, M., Ariav, Y., et al. (2008) mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes, 57, 945-957.
72. Kulke, M.H., Bergsland, E.K., &, Yao, J.C., (2009) Glycemic control in patients with insulinoma treated with everolimus. The New England Journal of Medicine, 360, 195-197.
73. Ferrer-Garcia, J.C., Tolosa-Torrens, M., Hernando-Melia, C., et al. (2011) Everolimus Resolves Hypoglycemia, Produces Hyperglycemia and Insulin Usage in a Diabetic Patient with Non-Resectable Malignant Insulinoma. Endocrine Practice, 17, 1-11.
74. Bourcier, M.E., Sherrod, A., DiGuardo, M., et al. (2009) Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. Journal of Clinical Endocrinology and Metabolism, 94, 3157-3162.
75. Pietras, K., &, Hanahan, D., (2005) A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. Journal of Clinical Oncology, 23, 939-952. (Pubitemid 46202314)
76. Raymond, E., Dahan, L., Raoul, J.L., et al. (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. The New England Journal of Medicine, 364, 501-513.
77. 68Ga- DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. Journal of Nuclear Medicine, 51, 669-673.
78. Korner, M., Eltschinger, V., Waser, B., et al. (2005) Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. American Journal of Surgical Pathology, 29, 1642-1651.
79. Sasano, H., Iida, S., &, Kasajima, A., (2010) Immunhistochemische Beurteilung von Somatostatinrezeptorsubtypen im Entnahmematerial neuroendokriner Tumoren. Der Pathologe, 31 (Suppl 2), 199-203.
80. Hofland, L.J., &, Lamberts, S.W., (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocrine Reviews, 24, 28-47. (Pubitemid 36223278)
81. Ong, G.S., Henley, D.E., Hurley, D., et al. (2010) Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. European Journal of Endocrinology, 162, 1001-1008.
82. 3] octreotate. European Journal of Nuclear Medicine and Molecular Imaging 35, 749-755.
83. Ekeblad, S., Sundin, A., Janson, E.T., et al. (2007) Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clinical Cancer Research, 13, 2986-2991. (Pubitemid 46849574)
84. Kulke, M.H., Stuart, K., Enzinger, P.C., et al. (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. Journal of Clinical Oncology, 24, 401-406. (Pubitemid 46630459)